Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EXAM trial (cabozantinib): what clinicians have said so far
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
- NCT00704730 ↗
- Completed
- Exelixis
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on EXAM (cabozantinib in unresectable, locally advanced or metastatic medullary thyroid cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EXAM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Thyroid Cancer
- Interventions
- XL184; Placebo
- Arms
- 1 · Experimental
- 2 · Placebo comparator
- Enrollment
- 330
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Exelixis
- Start
- Jun 2008
- Primary completion
- Oct 2011
- Results posted
- Yes
- Registry record
- NCT00704730 · updated Apr 20, 2021
Publications
linked from the registry- Schlumberger M, Elisei R, Muller S, Schoffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017 Nov 1;28(11):2813-2819. doi: 10.1093/annonc/mdx479. PubMed 29045520
- Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. PubMed 24002501